Viromed Medical AG Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	5.22	5.09	1.12	-	-	-
Revenue Growth	115.74%	352.27%	-	-	-	-
Cost of Revenue	2.97	2.8	1.41	-	-	-
Gross Profit	2.25	2.29	-0.29	-	-	-
Selling, General & Admin	0.97	0.86	0.4	0.09	0.04	-
Other Operating Expenses	2.62	1.72	2.56	0.27	0.12	0.01
Operating Expenses	4.11	3.11	3.21	0.36	0.16	0.01
Operating Income	-1.86	-0.83	-3.5	-0.36	-0.16	-0.01
Interest Expense	-0.23	-0.2	-0.72	-0	-0	-
Interest & Investment Income	0.34	0.33	0.11	-	-	-
Earnings From Equity Investments	-	-	-	0.25	-	-
Currency Exchange Gain (Loss)	-0	-0	-0	-	-	-
EBT Excluding Unusual Items	-1.76	-0.69	-4.11	-0.11	-0.16	-0.01
Gain (Loss) on Sale of Investments	-0	-0	-0	-	-	-
Pretax Income	-1.76	-0.69	-4.12	-0.11	-0.16	-0.01
Income Tax Expense	-2.1	-1.3	-1.02	-	-	-
Net Income	0.34	0.6	-3.09	-0.11	-0.16	-0.01
Net Income to Common	0.34	0.6	-3.09	-0.11	-0.16	-0.01
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	-	21	20	20	20	-
Shares Outstanding (Diluted)	-	21	20	20	20	-
Shares Change	-	4.94%	-	-	-	-
EPS (Basic)	-	0.03	-0.15	-0.01	-0.01	-
EPS (Diluted)	-	0.03	-0.15	-0.01	-0.01	-
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	43.12%	44.92%	-25.60%	-	-	-
Operating Margin	-35.60%	-16.23%	-311.14%	-	-	-
Profit Margin	6.56%	11.88%	-274.95%	-	-	-
EBITDA	-1.34	-0.3	-3.25	-	-	-
EBITDA Margin	-25.68%	-5.92%	-288.57%	-	-	-
D&A For EBITDA	0.52	0.52	0.25	-	-	-
EBIT	-1.86	-0.83	-3.5	-0.36	-0.16	-0.01
EBIT Margin	-35.60%	-16.23%	-	-	-	-